407 - Cardiac Troponin I Levels Following mRNA-1273 Vaccination in Participants 12 Through 30 Years of Age: Results from a Phase 4 Randomized, Placebo-Controlled Study

Presenting Author(s)

• SP

  Susan Pfeiffer, PA-C, MS

  Director, Clinical Development, Infectious Disease
  Moderna, Inc.
  Cambridge, Massachusetts, United States

  Slides

Co-Author(s)

• 

  Veronica Urdaneta, MD, MPH (she/her/hers)

  Global Clinical Safety Lead - COVID-19 Program/ Senior Director, Global Safety Physician
  Moderna, Inc.
  Cambridge, Massachusetts, United States
• XW

  Xiaowei Wang, PhD

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• BG

  Bethany Girard, Ph.D.

  Moderna, Inc.
  Cambridge, Massachusetts, United States
• FP

  Frances Priddy, MD, MPH (she/her/hers)

  Executive Director, Clinical Development
  Moderna, Inc.
  Cambridge, Massachusetts, United States
• MR

  Margaret Rhee, M.D.

  Velocity Clinical Research
  Cleveland, Ohio, United States
• SS

  Scott Striplin, MD

  Principal Investigator
  Velocity Clinical Research
  New Orleans, Louisiana, United States
• SC

  Spyros Chalkias, MD (he/him/his)

  Senior Medical Director
  Moderna, Inc.
  Cambridge, MA, United States